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Abstract 
Background: Cholangiocarcinoma is a highly lethal neoplasm for which the currently available 
chemotherapeutic agents are suboptimal. Numerous studies show that alterations in expression of genes 
related to mitotic spindle and mitotic checkpoint are involved in chromosomal instability and tumor 
progression in various malignancies. This study aimed to evaluate these genes in cholangiocarcinoma patients. 
Material and methods: Different public datasets were analyzed to examine the expression of 76 selected 
mitotic spindle checkpoint genes including Aurora Kinase A (AURKA) in cholangiocarcinoma. Afterwards, cell 
number counting, CCK-8 assay, and Caspase 3/7 assay were used to explore the antitumor effect of AURKA 
inhibitor Alisertib in vitro. In addition, xenograft model was used to evaluate the antitumor effect of Alisertib in 
vivo. Furthermore, siRNA mediated silencing of AURKA was used to verify the function of AURKA in 
cholangiocarcinoma. 
Results: Components of the mitotic spindle checkpoint, including AURKA, were broadly dysregulated in 
human cholangiocarcinoma. High AURKA mRNA expression was associated with poor survival in 
cholangiocarcinoma patients within different datasets. AURKA specific inhibitor Alisertib, inhibited cell growth, 
induced cell cycle arrest in G2/M phase, and promoted apoptosis in cholangiocarcinoma cell lines. Additionally, 
Alisertib also inhibited tumor growth in a cholangiocarcinoma xenograft mouse model. Furthermore, AURKA 
knockdown by siRNA recapitulated the antitumor effect of Alisertib. AURKA expression was also highly 
correlated with its interaction proteins Polo-like kinase 1(PLK1) and Targeting protein for xenopus kinesin-like 
protein2 (TPX2) in different cholangiocarcinoma datasets.  
Conclusions: Highly expressed AURKA confers poor outcomes in cholangiocarcinoma and may represent a 
rational therapeutic target. 
Key words: Aurora kinase A, Alisertib, Cholangiocarcinoma, mitotic spindle checkpoint, poor prognosis, 
molecular marker  
Introduction 
Cholangiocarcinoma is a highly malignant 
tumor with dismal prognosis. Despite recent 
advances in diagnosis and treatment, 5-year survival 
rate of cholangiocarcinoma does not increase 
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significantly and remains at 10% [1]. Gemcitabine- 
based chemotherapies are recommended for patients 
with inoperable cholangiocarcinoma [2]. However, 
long term outcome is still poor, highlighting the need 
for the identification of novel therapeutics for this 
neoplasm. 
Many studies show that alterations in expression 
of genes related to mitotic spindle and mitotic 
checkpoint are involved in chromosomal instability 
and tumor progression in various solid and 
hematologic malignancies [3-5]. However, despite the 
importance of the mitotic spindle checkpoint in 
cancer, detailed analyses of mitotic spindle 
checkpoint gene expression in cholangiocarcinoma 
has not yet been performed. 
Mammalian Aurora family of serine/threonine 
kinases are key regulators of mitotic progression and 
cell proliferation. Among the three members of the 
Aurora kinase family (Aurora kinase A, B, and C), 
Aurora kinase A (AURKA) and Aurora kinase B 
(AURKB) are expressed at detectable levels in somatic 
cells undergoing mitotic cell division. Aberrant 
Aurora kinase A activity has been implicated in 
oncogenic transformation through the development 
of chromosomal instability and tumor cell 
heterogeneity [6, 7]. Recent studies also reveal a novel 
non-mitotic role of Aurora kinase A activity in 
promoting tumor progression through regulating a 
number of key oncogenic signaling pathways [8, 9]. 
Therefore, AURKA represents an attractive target for 
cancer therapeutics.  
In the present study, we examined the 
expression of 76 selected mitotic spindle checkpoint 
genes known to be involved in various molecular 
mechanisms associated with the mitotic spindle 
checkpoint in cholangiocarcinoma [3]. Components of 
the mitotic spindle checkpoint, including AURKA, 
were broadly dysregulated in human cholangio-
carcinoma patients using The Cancer Genome Atlas 
(TCGA) or Gene Expression Omnibus (GEO) datasets. 
We also found that highly expressed AURKA was a 
negative prognostic marker of cholangiocarcinoma. 
We hypothesized that this can be exploited 
therapeutically with AURKA inhibition, and we 
tested the antitumor activity of the selective AURKA 
inhibitor Alisertib in vitro in cholangiocarcinoma cell 
lines and in vivo in a mouse xenograft model.  
Materials and Methods  
Reagents  
Alisertib was purchased from Selleck (Houston, 
TX, USA). Anti-β-actin primary antibody was 
purchased from Sigma Aldrich (St. Louis, MO, USA). 
Antibody against human AURKA (#14475) was 
purchased from Cell Signaling Technology (Beverly, 
MA, USA). Immobilon Western Chemiluminescent 
HRP detection kit was from Millipore (Burlington, 
MA, USA). Cell counting kit-8 (CCK-8) was from 
Dojindo Laboratories (Kyushu, Japan). Caspase-Glo 
3/7 assay kit was from Promega (Madison, WI, USA). 
Annexin V-FITC Apoptosis Detection kit was from 
BD Pharmingen (Franklin Lakes, NJ, USA). 
Lipofectamine RNAiMAX was from Invitrogen 
(Carlsbad, CA, USA). Cell culture medium was 
obtained from Gibco (Grand Island, NY, USA). Fetal 
bovine serum (FBS) was from Biological Industries 
(Kibbutz Beit Haemek, Israel). Cell extraction buffer 
was from Life Technologies (Grand Island, NY, USA). 
Alisertib was dissolved in DMSO to make a stock 
solution of 10 mM.  
The Cancer Genome Atlas (TCGA) and public 
microarray data analysis  
TCGA cholangiocarcinoma transcriptomic 
dataset consisting of 36 cholangiocarcinoma patients 
and 9 normal bile ducts was downloaded from the 
Firehose run of the Broad Genome Data Analysis 
Center on May 6, 2017 (http://gdac.broadinstitute. 
org). The TCGA data consists of 36 cholangiocarci-
noma samples and 9 normal bile duct tissue samples. 
Cholangiocarcinoma transcriptomic microarray 
dataset GSE107943 was built by the co-author [10], 
which consists of 30 intrahepatic cholangiocarcinoma 
surgical specimens and 28 non-cancerous 
surrounding liver specimens. In the dataset 
GSE107943, 2 molecular subtypes of iCCA with 
distinct clinicopathological differences were identi-
fied. Another public cholangiocarcinoma microarray 
profiling dataset GSE26566 was downloaded from the 
Gene Expression Omnibus (GEO). GSE26566 was 
built by Andersen et al from Copenhagen [11], which 
consists of 104 cholangiocarcinoma samples, 59 
non-cancerous surrounding liver samples, and 6 
normal bile duct samples. Through analyzing the 
dataset GSE26566, the author identified 2 prognostic 
categories of patients with CCA, each containing 2 
subclasses characterized by distinct gene expression 
profiles. Additionally, cholangiocarcinoma dataset 
(EGAD00001001693) constructed by Nakamura et al 
from Japan and stored in European Genome-phenome 
Archive database was analyzed to explore the 
association of AURKA mRNA expression with 
survival [12]. 
Cell culture 
Five human cholangiocarcinoma cell lines 
HCCC9810, HuCCT1, RBE, HuH28, and OZ were 
used. HuH28, OZ, and HuCCT1 were provided by 
Lewis R.Roberts (Mayo Clinic, MN, USA), which were 
 Journal of Cancer 2020, Vol. 11 
 
http://www.jcancer.org 
2243 
originally obtained from the Japanese Collection of 
Research Bioresources. RBE and HCCC9810 were 
obtained from Cell Bank of Chinese Academy of 
Sciences (Shanghai, China). Cell lines were 
authenticated using short tandem repeat profiling. All 
cholangiocarcinoma cell lines used were cultured in 
RPMI 1640 with 10% FBS and maintained at 37°C in 
the presence of 5% CO2.  
Cell proliferation and viability assay 
Cells were plated in 6-well plates at 1×105 
cells/well. After 24 h, drugs were added and cells 
were incubated for the indicated time. Cell 
proliferation was detected by cell number counting 
with trypan blue. Cell viability was detected by 
CCK-8 assay. Cells were seeded into 96-well plates at 
3000 cells/well in triplicate, cultured overnight then 
treated with drugs for indicated time. The CCK-8 
assay was performed as previously described [13].  
Colony formation assay 
Cells were plated at 500 cells/well in a 6-well 
plate. After 24 h, drugs were added and cells were 
incubated for 7 days. Cells were then fixed with 
methanol solution and stained with 0.5% crystal 
violet. The number of colonies, defined as ≥ 50 cells/ 
colony, was counted manually by light microscopy. 
Cell Cycle analysis 
Cells were seeded in 6-well plates at 2×105 
cells/well and treated with varying concentrations of 
Alisertib or transfected with siRNA targeting AURKA 
for 48-72 h. 
Cell cycle was analyzed using BD Cycletest Plus 
DNA Reagent Kit Cells according to the manu-
facturer’s instructions. Cell cycles were analyzed by 
using FlowJo software.  
Annexin V-FITC apoptosis assay 
Cells were seeded in 6-well plates at 2×105 
cells/well and treated with varying concentrations of 
Alisertib or transfected with siRNA targeting AURKA 
for 48-72 h. Apoptosis was assessed using the 
Annexin V-FITC Apoptosis Detection kit and 
performed according to the manufacturer’s instruct-
tions. Data were analyzed using FlowJo software.  
Caspase 3/7 activity assay 
Caspase 3/7 activity was analyzed using the 
Caspase-Glo 3/7 assay kit according to the 
manufacturer’s instructions. 3000 cells were seeded 
into 96-well white opaque plates and a corresponding 
optically clear 96-well plate, and then allowed to 
adhere overnight. The next day, cells were treated 
with varying concentrations of indicated drugs for 48 
h. At the end of the incubation time, Caspase-Glo 
reagent was added to each well. Plates were gently 
mixed and incubated for 1 h at room temperature. The 
luminescence was then measured in a GloMax 
Luminometer (Promega, Madison, WI). The 
corresponding 96-well clear plate was used to 
measure the relative number of viable cells with the 
CCK-8 assay. Caspase 3/7 activity was normalized to 
viable cell number. 
Western immunoblotting 
Whole-cell lysates were prepared in Cell 
extraction buffer, and western immunoblotting 
analysis was performed as previously described [13]. 
Twenty micrograms of protein were separated on a 
4-20% Tris-HCl gel and transferred to PVDF 
membranes. Membranes were probed with the 
appropriate primary antibodies. Blots were then 
incubated with horseradish peroxidase-conjugated 
secondary antibodies and signals were visualized 
using the HRP detection kit. β-actin was used as a 
loading control.  
RNA interfering  
Cells were grown in 6-well plates and 
transfected with 20 nM siRNA using Lipofectamine 
RNAiMAX (Life Technologies) according to the 
manufacturer’s protocol. The siRNA AURKA (5’- 
GAAGAGAGTTATTCATAGA-3’) and siRNA control 
duplexes were purchased from RiboBio (RiboBio Co. 
Ltd., Guangzhou, China). 
Xenograft in nude mice 
Nude mice were purchased from Beijing Vital 
River Laboratory Animal Technology. The animal 
experiments were approved by the Institutional 
Animal Care and Use Committee. HuCCT1 cells (3 × 
106 cells) were suspended in 100 μl serum free 
medium, mixed with 100 μl Matrigel, and injected 
subcutaneously into the right flank of 4- to 6-week old 
female nude mice. After 10 days when the tumor size 
reached about 150-200 mm3, mice were randomized 
into two groups with 6 mice in each group. Mice were 
treated by 30 mg/kg of Alisertib (daily × 5 days per 
week, by oral gavage) or vehicle control (10% 
2-hydroxypropyl-b-cyclodextrin and 1% sodium 
bicarbonate, daily × 5 days per week, by oral gavage). 
Tumor volume and animal weight were measured 
twice a week. Tumor size was measured with digital 
caliper and calculated as V = L×S2/2 (where L is the 
longest diameter and S is the shortest diameter). 
Statistics 
Statistical tests were conducted with GraphPad 
Prism 6.0. The IC50 was calculated using nonlinear 
regression analysis in Prism 6.0. For comparisons 
between two groups, parametric Student’s t test or 
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nonparametric Mann-Whitney test were used. In 
experiments involving more than two groups, 
one-way ANOVA with a Turkey post hoc test was 
used. Kaplan-Meier survival analysis was used to 
estimate the survival distributions. The log-rank test 
was used to assess the statistical significance between 
the stratified survival groups. The correlations of gene 
expression were analyzed using Pearson correlation. 
Results were considered statistically significant at 
P<0.05.  
Results 
Mitotic spindle checkpoint genes were 
overexpressed in cholangiocarcinoma 
To identify the differentially expressed mitotic 
spindle checkpoint genes in cholangiocarcinoma 
tissues, we analyzed the TCGA cholangiocarcinoma 
and normal bile duct tissue RNA sequencing data and 
two microarray datasets (GSE107943 and GSE26566).  
Further analyses of these data showed that 57 
genes were differentially expressed in the TCGA 
dataset (50 upregulated and 7 downregulated, 
Fig.1A); 74 were differentially expressed in the 
GSE107943 dataset (74 upregulated and 0 
downregulated, Fig.1B); 30 were dysregulated in the 
GSE26566 dataset (30 upregulated and 0 
downregulated, Fig.1C). Further Venn analyses 
revealed that 29 genes (38.2%) were consistently 
upregulated in three datasets (Fig.1D). These findings 
indicate that components of the mitotic spindle 
checkpoint were broadly dysregulated in human 
cholangiocarcinoma, and part of those genes may be 
useful biomarkers for cholangiocarcinoma diagnosis. 
AURKA expression was significantly 
upregulated in cholangiocarcinoma, 
correlated with cell proliferation, and 
predicted poor survival 
Given the oncogenic potential of AURKA in 
other cancers and a highly specific inhibitor of 
AURKA is already available, we focused our further 
descriptive and functional analyses on AURKA. As 
shown in Fig. 2A, AURKA mRNA was markedly 
higher in the cholangiocarcinoma compared to that in 
the normal bile ducts or surrounding normal livers in 
all three datasets. Next, analyses using data of TCGA, 
GSE26566, and GSE107943 revealed mRNA 
expression levels of AURKA positively correlated 
with that of the proliferative marker Ki-67 (Fig. 2B). 
Furthermore, we analyzed the association of AURKA 
mRNA expression with cholangiocarcinoma 
outcomes in different cohorts using the mean AURKA 
expression value as a cut-off. In the South Korea 
Cohort (GSE107943), Kaplan-Meier survival 
demonstrated that high AURKA mRNA expression 
was strongly correlated with reduced disease free 
survival (DFS) time (P<0.0001) and overall survival 
(OS) time (P=0.0145) (Fig. 3A). In the Copenhagen 
cohort (GSE26566), AURKA mRNA expression also 
correlated with cholangiocarcinoma overall survival 
time. Patients with higher AURKA mRNA levels in 
cholangiocarcinoma tumors showed significantly 
shorter overall survival time than those with lower 
levels of AURKA (P=0.0232) (Fig. 3B). Further 
analysis was carried out using a publicly available 
transcriptomic dataset (Japan Cohort), which also 
showed high AURKA mRNA expression was 
significantly correlated with reduced overall survival 
time (P=0.0271) (Fig. 3C). Collectively, these data 
indicate that highly expressed AURKA may be a 
negative prognostic factor in cholangiocarcinoma.  
AURKA specific inhibitor Alisertib inhibited 
cell proliferation of cholangiocarcinoma cells 
in vitro 
To determine whether AURKA may represent an 
appropriate therapeutic target in cholangiocarcinoma, 
we initially screened a panel of cholangiocarcinoma 
cell lines with Alisertib, a highly selective AURKA 
inhibitor. Cholangiocarcinoma cell lines exhibited 
different sensitivity to AURKA inhibition (Fig. 4A) 
with IC50 values ranging from 38.4 nM to 303.1 nM 
(Fig. 4B). We compared their IC50 in vitro with their 
Cmax (maximum concentration) in blood using 
previous available preclinical pharmacokinetic data 
and phase I human clinical trial [14, 15]. We found 
their IC50s were achievable in vivo. Because 
HCCC9810 and HuCCT1 cell lines were most 
sensitive to Alisertib, we further assessed the 
antitumor effect of Alisertib in these two cell lines. As 
shown in Fig. 4C, 100 nM Alisertib time-dependently 
inhibited cell proliferation of HCCC9810 and 
HuCCT1. CCK-8 viability assay and colony formation 
assay also verified the tumor inhibitory effect of 
Alisertib in these two cell lines (Fig. 4D and 4E). 
Alisertib inhibited cholangiocarcinoma growth 
in a xenograft mouse model  
We next determined the effect of Alisertib on the 
growth of cholangiocarcinoma xenografts in vivo. To 
test this, we utilized the HuCCT1 cell line which 
exhibits sensitivity to Alisertib in vitro, and which has 
a tumorigenicity in vivo. HuCCT1 cells were engrafted 
into the right flank of nude mice. Ten days after 
implantation when tumors reached a size of 
approximately 150- 200 mm3, mice were randomly 
divided into 2 groups. Alisertib treatment induced a 
statistically significant inhibition of tumor growth 
when assessed by relative tumor volume change at 
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days 14, 18, 21 and 25 (Fig. 4F) and when assessed by 
tumor volume at the completion of the experiment on 
day 25 (Fig. 4G and Supplemental Fig. 1). Notably, 
Alisertib did not affect mice weight (Fig.4H). 
 
 
Figure 1. Mitotic spindle checkpoint genes were broadly overexpressed in human cholangiocarcinoma. A) A heat map was drawn to show the differentially 
expressed gene transcripts related to the mitotic spindle checkpoint in cholangiocarcinoma tissues and normal bile duct tissues in the TCGA RNA sequencing data. B-C) Heat 
maps were drawn to show the differentially expressed gene transcripts related to the mitotic spindle checkpoint in cholangiocarcinoma tissues, normal surrounding liver tissues 
and normal bile duct tissues in the GSE107943 and GSE26566 datasets. D) Venn diagram of dysregulated genes in TCGA, GSE107943, and GSE26566 datasets. 
 
Figure 2. AURKA expression was upregulated in cholangiocarcinoma and correlated with cell proliferation. A) AURKA mRNA expression was markedly upregulated in 
cholangiocarcinoma in TCGA, GSE107943, and GSE26566 datasets. B) The expression level of AURKA showed a significant positive correlation with Ki-67 expression in the 
dataset of TCGA, GSE107943, and GSE26566. The r and P values were determined by Pearson correlation analysis. 
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Figure 3. High AURKA expression correlated with poor survival in cholangiocarcinoma tumors. A) Kaplan-Meier survival curves showing the relationship 
between AUKRA mRNA expression and disease free survival and overall survival in the Korea cohort GSE107943 (n = 30). B) Kaplan-Meier survival curves showing the 
relationship between AURKA mRNA expression and overall survival in the Copenhagen cohort GSE26566 (n = 102). C) Kaplan-Meier survival curves showing the relationship 
between AURKA mRNA expression and overall survival in the Japan cohort EGAD00001001693 (n=111). 
 
Figure 4. Effect of Alisertib on tumor growth in vitro and in vivo. A) Cells were treated with Alisertib at different concentrations (10nM–10 μM) for 72 h and cell 
proliferation was determined by cell number counting. B) IC50 values of Alisertib in cholangiocarcinoma cells following 72 h of treatment. C) Time–response curves of 
HCCC9810 and HuCCT1 cell lines to Alisertib treatment (100 nM). D) HCCC9810 and HuCCT1 were treated with Alisertib at different concentrations for 72 h and cell 
viability was determined by CCK-8 assay. E) Plated HCCC9810 and HuCCT1 were treated with Alisertib for 7 days and colonies were stained with 0.5% crystal violet. F) 
HuCCT1 cells were injected subcutaneously into the right flanks of athymic nude mice. When tumors reached a size of approximately150- 200 mm3, mice were randomized to 
receive vehicle (n=6) or Alisertib (n=6) by oral gavage. Tumor volume was measured every 3-4 days. Values shown are the mean difference in tumor volume ± SEM. G) Tumor 
volume in each group on day 25. Data represented are mean ± min/max group values. H) Change of body weight in mice treated with vehicle control or Alisertib. All results are 
presented as mean ± SEM from 3 independent experiments unless otherwise pointed, * P < 0.05, ** P < 0.01, compared with control. 
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Alisertib induced G2/M phase arrest and 
apoptosis of cholangiocarcinoma cells 
Then, we aimed to explore the mechanism 
underlying the tumor-suppressing effect of Alisertib. 
Treatment with Alisertib for 48 h induced cell cycle 
arrest in G2/M phase in both HCCC9810 and 
HuCCT1 cells (Fig. 5A). Significant apoptosis were 
found after treatment of 100 nM Alisertib for 72 h in 
both cell lines (Fig. 5B). Furthermore, treatment with 
Alisertib for 48 h significantly increased Caspase 3/7 
activity, suggesting Alisertib may induce caspase- 
dependent apoptosis in cholangiocarcinoma cells (Fig. 
5C). Collectively, these data demonstrated that 
AURKA played a tumor promoting role in cholangio-
carcinoma by regulating cell cycle and apoptosis. 
AURKA knockdown was sufficient to 
recapitulate the antitumor effect of Alisertib 
Our results support that AURKA sustains 
proliferation in cholangiocarcinoma. We depleted 
AURKA to further elucidate Aurora kinase A is 
responsible for the cell proliferation of cholangio-
carcinoma cells. SiRNA mediated suppression of 
AURKA were conducted in five cholangiocarcinoma 
cell lines and resulted in prominent reduction of 
protein expression at 48 hours post transfection (Fig. 
6A). AURKA knockdown caused a significant 
reduction in cell proliferation (Fig. 6B). HCCC9810 
and HuCCT1 cells were most sensitive to AURKA 
knockdown consistent with their response to AURKA 
inhibitor Alisertib. CCK-8 assay also showed that 
siRNA mediated knock down of AURKA inhibited 
cell viability in these cells (Fig. 6C). Furthermore, 
AUKRA silencing caused cell cycle arrest in G2/M 
phase, induced apoptosis and activated Caspase 3/7 
activity in HCCC9810 cells (Fig. 6D). Taken together, 
our results showed that AURKA silencing by siRNA 
is sufficient to recapitulate the oncosuppressive effects 
of AURKA chemical inhibition on cholangio-
carcinoma cells. 
 
 
Figure 5. AURKA inhibition induced cell cycle arrest and apoptosis. A) Quantification of percentage of HCCC9810 and HuCCT1 cells in different cell cycle phases 
following treatment with Alisertib for 48 h. B) Apoptosis analysis via Annexin V/propidium iodide staining of cholangiocarcinoma cells at 100 nM Alisertib following 72 h of 
treatment. C) Apoptosis analysis via Caspase 3/7 activity of cholangiocarcinoma cells at various concentrations of Alisertib following 48 h of treatment. All data shown were Mean 
± SEM from 3 independent experiments, * P < 0.05, ** P < 0.01, compared with control. 
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Figure 6. Knockdown of AURKA diminished cell proliferation, viability, and increased G2/M phase arrest and apoptosis. A) Western immunoblotting analysis 
of AURKA protein expression 48 h post-siRNA knockdown of AURKA in cholangiocarcinoma cells. B) Cell proliferation following 72 h AUKRA knockdown in 
cholangiocarcinoma cells. Cell proliferation was determined by cell number counting. Cells number was normalized to siControl (siCont). C) CCK-8 cell viability assay following 
72 h AURKA knockdown in HCCC9810 and HuCCT1 cells (n= 3). Cell viability was normalized to siControl. D) Cell cycle analysis following 48 h AURKA knockdown in 
HCCC9810 cells. E) Annexin V-PI assay and Caspase 3/7 activity analysis of apoptosis following 72 h AURKA knockdown in HCCC9810 cells. All data shown were Mean ± SEM 
from 3 independent experiments, * P < 0.05, ** P < 0.01, compared with control. 
 
AURKA interaction genes Targeting protein 
for xenopus kinesin-like protein 2 (TPX2) and 
Polo-like kinase 1 (PLK1) correlated with 
AURKA expression in cholangiocarcinoma 
To identify network genes that may collaborate 
with AURKA in promoting cholangiocarcinoma, we 
generated a Genetic interaction network of AURKA 
using the online tool GeneMANIA (www.genemania. 
org). Among the top 20 genes that may have an 
interaction with AURKA were TPX2 and PLK1 (Fig. 
7A). These are two well-established co-factors of 
AURKA in various cell lineages but not been reported 
in cholangiocarcinoma. We sought to confirm the 
co-expression of TPX2, PLK1 and AURKA in 
cholangiocarcinoma datasets. Notably, both TPX2 and 
PLK1 were among the top 20 correlated genes with 
AURKA in the TCGA dataset of cholangiocarcinoma 
based on Person correlation analysis (Fig. 7B). 
Additionally, we verified a significantly high 
correlation of AURKA with TPX2 and PLK1 in the 
dataset of GSE107943 (r= 0.57 and 0.57 respectively) 
and GSE26566 (r=0.79 and 0.71 respectively) (Fig. 7C).  
Discussion 
Despite cholangiocarcinoma being one of the 
most malignant cancers, the molecular processes that 
underlie its development are relatively understudied. 
Limited success has so far been achieved in respect of 
diagnostic and prognostic markers in cholangio-
carcinoma. In addition, no targeted therapy has so far 
been approved against this neoplasm. To identify new 
putative drug targets, we compared gene expression 
profiles between cholangiocarcinoma tissues and 
normal bile ducts and identified global upregulation 
of mitotic spindle-associated genes. To our know-
ledge, this is the first report of a broad overexpression 
of mitotic spindle checkpoint components as a 
common characteristic of human cholangiocarcinoma. 
AURKA play key roles in regulating mitotic 
entry, centrosome maturation and separation, and 
bipolar spindle assembly. AURKA has been reported 
to be overexpressed in various cancers and has been 
shown to be a promising target in cancer [16-23]. 
However, no study specifically investigates the role 
and function of AURKA in cholangiocarcinoma. In 
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this study, we found that AURKA was highly 
expressed in cholangiocarcinoma and high AURKA 
expression was a good predictor of poor prognosis in 
cholangiocarcinoma. The negative prognostic role of 
AURKA in cholangiocarcinoma was solid as it was 
validated in three different cholangiocarcinoma 
cohorts. AURKA expression was also highly 
correlated with expression of proliferation marker 
Ki-67. Hence, AURKA expression is associated with 
enhanced proliferation of tumor cells. Next, we 
evaluated the impact of the AURKA inhibitor on 
cholangiocarcinoma cells in vitro. Alisertib (MLN8237) 
is an orally available ATP-competitive, highly 
selective inhibitor of AURKA (40-fold selective for 
AURKA compared with AURKB) [24]. Clinical trials 
testing Alisertib as a single agent or in combination 
with conventional chemotherapies are ongoing for the 
treatment of various malignancies [14, 25-33]. Of the 
entire AURKA inhibitors, only Alisertib has 
proceeded to phase III evaluation [34]. Therefore, we 
chose Alisertib for further studies. Application of 
Alisertib on cholangiocarcinoma cells inhibited cell 
growth and induced apoptosis in vitro. As a key 
regulator of cell cycle, AURKA regulates G2/M 
transition. Consistent with this, we found Alisertib 
arrested cells in G2/M phase. Additionally, we 
showed the in vivo capacity of Alisertib to arrest 
tumor growth in a mouse xenograft model of 
cholangiocarcinoma without obvious toxicity. Finally, 
AURKA depletion through siRNA achieved a similar 
effect with Alisertib, excluding the off target effect of 
Alisertib. Therefore, both in vitro and in vivo results 
support AURKA might be an effective therapeutic 
target in cholangiocarcinoma. 
 
 
Figure 7. AURKA correlated with TPX2 and PLK1. A) Genetic interaction network of AURKA generated with the help of the GeneMANIA online tool. The top 20 genes 
were shown. Blue and pink lines denote pathways and physical interactions, respectively. B) Top 20 correlated genes with AURKA in the TCGA dataset of cholangiocarcinoma 
based on the Person’s analysis. C) The expression level of AURKA showed a significant positive correlation with TPX2 and PLK1 expression in the dataset of GSE107943 and 
GSE26566. The r and P values were determined by Pearson correlation analysis. 
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Our study was consistent with a recent high- 
throughput screening study which showed that 
Aurora kinase inhibitors were effective in all 
cholangiocarcinoma cell lines tested [35]. AURKA 
inhibition is attractive in cholangiocarcinoma as it has 
been shown to interact with and control a variety of 
proteins that play key roles in cholangiocarcinoma 
pathogenesis such as STAT3 [36] and Mcl-1[22].  
 Although the AURKA currently represent the 
most accessible therapeutic target among the genes 
we identified, other members of the mitotic spindle 
checkpoint may warrant further study as potential 
prognostic markers of disease or alternate drug 
targets.  
Our data demonstrate that AURKA was highly 
expressed and associated with poor prognosis in 
cholangiocarcinoma. Phenotypic changes post kinase 
inhibition or depletion indicates that AUKRA was 
involved in mediating cell proliferation, cell cycle 
progression, and apoptosis resistance. Furthermore, 
inhibition of AURKA using a highly specific small 
inhibitor Alisertib has proven here to be promising in 
targeting cholangiocarcinoma. Considering the lack of 
established targeted therapeutics against cholangio-
carcinoma, we propose that AURKA may be a 
potential prognostic marker and effective therapeutic 
target for cholangiocarcinoma. In addition, we 
identified spindle checkpoint dysregulation as a 
common feature of human cholangiocarcinoma. We 
believe that the spindle assembly checkpoint in 
human cholangiocarcinoma warrants further 
investigation to explore the anticancer potential of 
drugs that target this pathway. 
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